Holen Sie sich die Stockscreener-App
14.52
6.92%
-1.08
Schlusskurs vom Vortag:
$15.60
Offen:
$15.21
24-Stunden-Volumen:
23.34M
Relative Volume:
1.07
Marktkapitalisierung:
$3.31B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
21.04
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
-7.10%
1M Leistung:
-51.08%
6M Leistung:
-67.01%
1J Leistung:
-64.88%
1-Tages-Spanne:
$14.48
$15.29
1-Wochen-Bereich:
$13.74
$16.46
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
14.52 | 3.56B | 1.78B | 164.40M | 236.51M | 0.69 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.75 | 58.54B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
131.10 | 54.78B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
11.07 | 47.92B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.86 | 39.33B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
503.90 | 21.68B | 3.13B | 1.27B | 1.12B | 26.39 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026 - FinancialContent
The Complicated Legal Battle Between Novo Nordisk and Hims & Hers - The Fashion Law
Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play - TechStock²
Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore - Yahoo Finance
Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore - The Motley Fool
The Law Offices of Frank R. Cruz Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors - The AI Journal
Hims & Hers Posts Robust Growth Boosted by New Acquisition - timothysykes.com
HIMS vs. AMWL: Which Telehealth Stock Is the Better Investment Now? - The Globe and Mail
Barclays Lowers Price Target for HIMS to $25, Maintains Overweig - GuruFocus
Morgan Stanley Lowers Price Target for HIMS to $21 | HIMS Stock News - GuruFocus
Hims & Hers Health: The GLP-1 Party Is Over (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health, Inc. (NYSE:HIMS) Q4 2025 Earnings Call Transcript - Insider Monkey
Discipline and Rules-Based Execution in HIMS Response - Stock Traders Daily
Hims And Hers Balances GLP 1 Scrutiny With Eucalyptus Expansion Plans - Yahoo Finance
Regulatory Scrutiny of Compounded Drugs Puts Hims & Hers’ Growth, Partnerships, and Liability Risk in the Spotlight - TipRanks
Bronstein, Gewirtz & Grossman, LLC Is Investigating Hims & Hers Health, Inc. (HIMS) And Encourages Shareholders to Connect - ACCESS Newswire
Hims & Hers Earnings Call Signals Growth Amid Risks - TipRanks
These Stocks Are Today’s Movers: AMD, Hims & Hers, Keysight, IBM, Kratos, Vir Biotechnology, Whirlpool, and More - Barron's
Earnings live: Home Depot stock climbs after earnings beat, Hims & Hers slides, Constellation Energy rises - Yahoo Finance
HIMS Analyst Rating Update: Leerink Partners Lowers Price Target - GuruFocus
Hims & Hers Health: Don't Get Lost In The Weeds (NYSE:HIMS) - Seeking Alpha
HIMS: Analyst TD Cowen Lowers Price Target to $17.00 | HIMS Stoc - GuruFocus
Hims & Hers Health: Great Vision, Now On Sale -- Here's Why I'm Upgrading (NYSE:HIMS) - Seeking Alpha
HIMS Analyst Rating Update: Citigroup Lowers Price Target | HIMS Stock News - GuruFocus
Hims & Hers Stock Faces Heavy Sell-Off Amid SEC Probe Into GLP-1 Disclosures - GuruFocus
HIMS Stock Plummets After Wall Street Downgrade, Price Target Cuts Following 'Disappointing' Q4 Report - Stocktwits
HIMS: BTIG Downgrades Hims & Hers Health to Neutral | HIMS Stock News - GuruFocus
Jefferies holds Hims and Hers stock rating at Hold on guidance concerns - Investing.com Nigeria
Hims & Hers Health Analysts Cut Their Forecasts After Q4 Results - Benzinga
Hims & Hers Stock Slips Despite Q4 Earnings Beat, Margins Contract - Yahoo Finance
AMD, Hims & Hers, Keysight, Novo Nordisk, IBM, Kratos, Vir, and More Movers - Barron's
Truist Securities Reiterates Hold Rating on HIMS, Lowers Price T - GuruFocus
Truist cuts Hims and Hers stock price target on quarterly ramp concerns - Investing.com India
Evercore ISI Group Lowers Price Target for Hims & Hers Health (H - GuruFocus
Hims & Hers Health (HIMS) Stock Plunges 7-9% to Near $14 After Soft Q1 2026 Guidance Despite Q4 Beat - International Business Times Australia
Hims & Hers Faces Investor Scrutiny Amid Regulatory and Growth Challenges - AD HOC NEWS
Hims & Hers Health (NYSE:HIMS) Trading Down 6.3% After Analyst Downgrade - MarketBeat
Biggest stock movers Tuesday: HIMS, VIR, CLVT, and more - Seeking Alpha
Hims & Hers Stock Drops. Why Earnings Are Underwhelming Investors. - Barron's
AMD, Hims & Hers, Home Depot, Kratos, Novo Nordisk, IBM, Keysight, Vir Biotechnology, and More Movers - Barron's
Meta, AMD announce chip partnership, Novo Nordisk cuts US GLP-1 prices - Yahoo Finance
KeyBanc maintains Hims and Hers stock rating on revenue outlook - Investing.com
Hims & Hers Health Stock (HIMS) Opinions on Q4 Earnings Release - Quiver Quantitative
Novo Nordisk: Investors Focusing On CagriSema Results Are Missing The Big Picture (NVO) - Seeking Alpha
Hims & Hers Health After The GLP-1 Collapse - Seeking Alpha
Hims & Hers Stock StumblesCautions About Pressure Due To Super Bowl Ad, Change In Shipping Cadences - Benzinga
Hims & Hers Health, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Hims & Hers Health (NYSE:HIMS) Cut to "Neutral" at BTIG Research - MarketBeat
Earnings live: Hims & Hers stock slides, Domino's rises as investors await crucial update from Nvidia - Yahoo Finance
AMD, Home Depot, Novo Nordisk, Hims & Hers, Keysight, Vir Biotechnology, and More Movers - Barron's
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.37%
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):